Loading…
Loading…
INNO (Harbor Disruptive Innovation ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Under normal market conditions, the fund invests primarily in equity securities, principally common stocks, of companies selected based on their potential for growth tied to disruptive innovation. The adviser defines “disruptive innovation” as the development of new products, services, technologies and/or other advancements that could disrupt and displace existing businesses and business models over time. While the fund invests primarily in securities of U.S. companies, it may invest up to 25% of its assets in foreign securities, including those located in emerging market countries.
Is INNO's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year. The FDA's Center for Veterinary Medicine (CVM) assesses annual fees for animal drug applications.
HERZLIYA, Israel and CALGARY, AB, Feb. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial" in the esteemed peer reviewed journal Frontiers in veterinary science (https://doi.org/10.3389/fvets.2025.1746266) (1). Key findings include: Significant improvement in behavior/function reported by owners (p = 0.0217), with 100% of dogs showing improved function after LPT-CBD vs 25% after placebo.
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on
Brookshire, Texas, Dec. 13, 2024 (GLOBE NEWSWIRE) -- INNO HOLDINGS INC. (“INNO” or the “Company”) (NASDAQ : INHD) is a trade-focused building technology company dedicated to revolutionizing the construction industry with its proprietary cold-formed steel framing technology, artificial intelligence (“AI”)-driven design, and advanced automation to deliver innovative and efficient building solutions. In addition to its existing business, the Company is now developing a new venture in electronic products trading while expanding its sales and distribution network across Asia. INNO consistently seeks innovative ways to enhance services and technologies and delivers high-quality products to its clients.
As recent advancements in are AI top of mind, many investors are looking to invest in disruptive innovation ETFs. There are many disruptive innovation ETFs available to investors.